found that despite the high prevalence of TP53 mutations in patients with MM, mutations in genes such as SF3B1/KIT/NF1 were not significantly associated with ICB response, suggesting the need for a comprehensive assessment combining TMB, PD-L1 expression, and lactate dehydrogenase (LDH) levels (73). This evidence concerns the gene TP53 and Miyoshi myopathy.